The educational platform is targeted at HCPs and their staff.
AbbVie launched a new learning platform designed to provide hcps, staff, and management about the company’s Allergan Aesthetics brand and products.1 The platform is available for free for all Allergan Aesthetics customers and is part of AbbVie’s investment in its AMI platform.
In a press release, U.S. Allergan Aesthetics senior vice president Glen Curran said, “Allergan Aesthetics designed AMI Business to meet providers where they are—supporting them with practical, business-focused education related to our products to complement their clinical expertise and help them grow their practices and deliver on patient needs. We are excited to provide these courses free of charge through AMI Online, giving all of our customers access to valuable resources that help them thrive in this dynamic industry."
Allergan Aesthetics develops, manufactures, and markets a portfolio of aesthetics brands and products, including facial injectables, body contouring, plastics, and skin care. The new learning platform will include educational material about the brand’s products, along with broader business-centered modules. This includes lessons on goals setting and creating lifetime patient partnerships.
In the same press release, board-certified plastic surgeon Dr. Joseph A. Russo said, “As a clinician and an educator in the aesthetic space, one of the biggest challenges we face is running and growing a business while improving our clinical skills to provide great outcomes for our patients. The AMI Business modules offer valuable insights for growing practices."
AbbVie also recently announced the winners of its first Migraine Career Catalyst Award, which is focused on telling the stories of migraine-sufferers navigating their careers while also managing their condition.2
In a press release issued at the time, AbbVie senior vice president and president of neuroscience and eye care Jag Dosanjh said, “Migraine can significantly affect an individual's career trajectory and long-term potential. Despite these challenges, the recipients of the inaugural AbbVie Migraine Career Catalyst Award have shared their remarkable determination to overcome disease-related obstacles as they work toward their professional aspirations. As the only company with three treatment options that collectively address the entire spectrum of migraine, we have a deep understanding of the challenges that people living with migraine can face in the workplace, and we're proud to support these individuals as they lead lives that transcend obstacles often imposed by the impact of the disease."
Melissa, a migraine-sufferer from Davis, West Virginia, is one of the winners of this year’s contest. In the same press release, she discussed her experience, saying, “Migraine impacted my life in ways that I hadn't anticipated. I spent most of my career working in state parks, outdoor recreation, and tourism. However, the demands of public service combined with the unpredictability of migraine have made life incredibly challenging. This award will allow me to create a mentorship program in my small town and share my experience and knowledge in outdoor recreation with the next generation, ensuring that they are better equipped to navigate the challenges of their careers with or without migraine."
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.